Remission in clinical trials (cases at end of followup).
| Study | Year | Disease Duration, mo | Followup, mo | Remission | Control | Treatment | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cases | Treatment | Remission (%) | Cases | Treatment | Remission (%) | |||||
| Monotherapy | ||||||||||
| Eberhardt50 | 1996 | 24 | 24 | ACR derivative | 22 | Placebo | 5 (12) | 21 | D-Penicillamine | 4 (12) |
| Rau51 | 1997 | 16 | 12 | ACR derivative | 87 | MTX | 10 (12) | 87 | GSTM | 21 (24) |
| Van Jaarsveld52 | 2000 | < 12 | 24 | ACR derivative | 107 | HCQ | 29 (27) | 105 | MTX (short lag) | 25 (24) |
| Choy18 | 2002 | < 12 | 12 | DAS28 | 55 | Diclofenac | 0 | 62 | SSZ | 0 |
| Monotherapy vs combination therapy | ||||||||||
| Boers1 | 1997 | < 24 | 12 | ACR | 76 | SSZ | 19 (24)* | 79 | SSZ/MTX/Pred | 24 (32)* |
| Möttönen7 | 1999 | < 24 | 24 | ACR | 98 | SSZ or MTX | 18 (18) | 97 | MTX/SSZ/HCQ/Pred | 36 (37) |
| Proudman53 | 2000 | < 12 | 12 | ACR | 42 | SSZ | 4 (10) | 40 | Methylpred | MTX/CSA/1A 5 (13) |
| Ferraccioli54 | 2002 | 16 | 36 | ACR | 42 | SSZ | 3 (7) | 42 | MTX/CsA | 4 (9) |
| Gerards55 | 2003 | < 36 | 12 | ACR | 60 | CsA | 4 (7) | 60 | CsA/MTX | 6 (10) |
| Wassenberg56 | 2005 | < 24 | 24 | ACR | 86 | DMARD | 8 (9) | 80 | DMARD/Pred | 13 (16) |
| St. Clair57 | 2004 | < 36 | 12 | DAS28 | 245 | MTX | 37 (15) | 325 | MTX/Infliximab | 101 (31) |
| Svensson24 | 2005 | < 12 | 24 | DAS28 | 126 | DMARD | 42 (33) | 116 | DMARD/Pred | 65 (56) |
| Allaart3 | 2006 | < 12 | 24 | DAS44 | 126 | DMARD | 58 (46) | 128 | MTX/Infliximab | 54 (42) |
| Breedveld6 | 2006 | < 36 | 24 | DAS28 | 257 | MTX | 64 (25) | 268 | MTX/Adalimumab | 131 (49) |
| Choy2 | 2008 | < 24 | 24 | DAS28 | 117 | MTX | 21 (18) | 116 | MTX/CsA/Pred | 32 (28) |
| Emery4 | 2008 | < 24 | 12 | DAS28 | 263 | MTX | 73 (28) | 265 | MTX/Etanercept | 132 (50) |
| Hetland19 | 2006 | < 6 | 12 | 1. DAS28 | 68 | MTX/IA | 1. 23 (34) | 69 | MTX/CsA/IA/steroids | 1.30 (43) |
| 2. ACR | Steroids | 2. 19 (28) | 2.24 (35) | |||||||
| Combination vs combination therapy | ||||||||||
| Verstappen58 | 2007 | < 12 | 24 | ACR derivative | 148 | Conventional MTX +/– CsA | 55 (37) | 151 | Intensive MTX +/– CsA | 76 (50) |
| Saunders59 | 2008 | Mean 11.5† | 12 | DAS28 | 44 | Step up | 21 (45) | 47 | Parallel | 16 (33) |
| Verschueren20** | 2008 | < 12 | 12 | DAS28 | 17 | Step up | No values | 46 | Step down | No values |
↵* Achieving remission at some point during followup (probable and definite remissions included).
↵** Not randomized. Inclusion criteria of symptoms < 5 years but mean disease duration < 12 months (SD < 12 mo). GSTM: Gold sodium thiomalate; MTX: methotrexate; HCQ: hydroxychloroquine; SSZ: sulfasalazine; Methylpred: methylprednisolone; Pred: prednisolone; CsA: cyclosporin A.